Trials / Suspended
SuspendedNCT00607711
Study of Oral Palifosfamide Tris in Solid Tumors
A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oral palifosfamide tris | Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm. |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2008-02-06
- Last updated
- 2008-05-05
Source: ClinicalTrials.gov record NCT00607711. Inclusion in this directory is not an endorsement.